Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trialTony Mok, Nelly Cherciu, Igor Bondarenko et al.|The Lancet|2019Cited by 3.3k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialKohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al.|The Lancet|2018Cited by 1.3k
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trialThomas Powles, Felipe Reyes, Tibor Csőszi et al.|The Lancet Oncology|2021Cited by 645
Immunotherapy in NSCLC: A Promising and Revolutionary WeaponChristian Rolfo, Mauricio Mahave, Christian Caglevic et al.|Advances in experimental medicine and biology|2017Cited by 143
Takotsubo cardiomyopathy Afatinib-related in a non-small cell lung cancer patient: Case reportGerman E. Ramos, Manuel E. Rodríguez, Christian Caglevic et al.|Frontiers in Cardiovascular Medicine|2022Cited by 8